Tandem Capital Management’s Integra LifeSciences IART Stock Holding History

Tandem Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,140	Closed	-$366K	–	113
2024 Q3	$366K	Sell	20,140 -6,946	-26%	-$161K	0.19%	96
2024 Q2	$781K	Sell	27,086 -11,765	-30%	-$349K	0.43%	65
2024 Q1	$1.38M	Hold	38,851	–	–	0.78%	40
2023 Q4	$1.69M	Buy	38,851 +1,058	+3%	+$41.6K	1.05%	37
2023 Q3	$1.44M	Buy	37,793 +2,380	+7%	+$100K	0.99%	38
2023 Q2	$1.46M	Buy	35,413 +1,286	+4%	+$61.9K	0.95%	40
2023 Q1	$1.96M	Buy	34,127 +3,000	+10%	+$169K	1.38%	26
2022 Q4	$1.75M	Buy	31,127 +3,924	+14%	+$200K	1.38%	28
2022 Q3	$1.17M	Buy	27,203 +4,440	+20%	+$227K	0.98%	37
2022 Q2	$1.23M	Buy	22,763 +785	+4%	+$47.1K	0.99%	35
2022 Q1	$1.33M	Buy	+21,978	New	+$1.45M	0.92%	37

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tandem Capital Management's IART Position: Q4 2024 in Review

Tandem Capital Management sold out of Integra LifeSciences (IART) in Q4 2024, closing a stake of 20,140 shares — an estimated $366K sold.

Tandem Capital Management first reported a position in IART in Q1 2022 and held it in 11 quarters. The position peaked at $1.96M in Q1 2023. 223 funds tracked by Wall St. Rank hold IART as of Q4 2024.

Tandem Capital Management reported no remaining Integra LifeSciences position as of Q4 2024 after selling out during the quarter.
Tandem Capital Management sold 20,140 Integra LifeSciences shares in Q4 2024, an estimated $366K.
Tandem Capital Management first reported a position in Integra LifeSciences in Q1 2022 and held it in 11 quarters.
Tandem Capital Management's Integra LifeSciences position peaked at $1.96M in Q1 2023.
223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2024.

Based on Tandem Capital Management's 13F filing for Q4 2024, filed 27 Jan 2025.